Search
-
Futurapolis Santé 2023: New feats of health science
The Futurapolis Santé health event returns to Montpellier on October 13-14, 2023, at the Opéra Comédie building.
-
Euro-Africa Montpellier Biennial
Following the success of the Africa-France Summit, Montpellier is proud to host and co-organize the first Euro-Africa Biennial in the fall of 2023. It will be a key week for bringing together the E...
-
SPECIFIC POLYMERS, 20 years supporting sustainable innovation
The SPECIFIC POLYMERS research center, celebrating its 20th anniversary on June 8 at Domaine Décalage in Saint Aunès, is taking a decisive step forward by applying its unique expertise to new energ...
-
The MedVallée roadmap respected to the letter
Just ten months after its official launch, the MedVallée excellence hub in global health has already started working on 19 of its 30 assigned actions. Ten of those have already been completed. The ...
-
"Prix Initiative Startup" celebrates its tenth anniversary in style
The four winners of this anniversary edition are BeatHealth, Beyond Words, Linup Ocean, and PimpUp. Created by the Montpellier Méditerranée Rotary Club with Montpellier BIC, these awards give winni...
-
Montpellier selected for University-Hospital Institute dedicated to autoimmune diseases
As part of Plan France 2030, Montpellier has been chosen to host “Immun4Cure”, a University-Hospital Institute (IHU) dedicated to autoimmune diseases and innovative immunotherapies.
-
Biomarker days: people as decision-makers regarding their own health
The University of Montpellier’s Biohealth research cluster, AD'OCC Regional Agency, and Eurobiomed Competitiveness Cluster are organizing the 7th Biomarker Days.
-
Medincell : historical succes in the heart of MedVallée
MedinCell and its partner TEVA announced that US FDA approuved UZEDY™, a long-acting injectable medication for treating schizophrenia. MedinCell also raised 25 million euros.
-
Medincell: historical success in the heart of MedVallée
MedinCell and its partner TEVA announced that US FDA approuved UZEDY™, a long-acting injectable medication for treating schizophrenia. MedinCell also raised 25 million euros.
-
MEDINCELL: HISTORICAL SUCCESS IN THE HEART OF MEDVALLÉE
On April 28, the pharmaceutical company MedinCell and its partner TEVA announced that the US Food and Drug Administration (FDA) approved a long-acting injectable medication for treating schizophren...